StockNews.com Downgrades Amneal Pharmaceuticals (NASDAQ:AMRX) to Hold

StockNews.com lowered shares of Amneal Pharmaceuticals (NASDAQ:AMRX – Get Rating) from a buy rating to a hold rating in a report published on Friday.

NASDAQ AMRX opened at $3.47 on Friday. The company has a debt-to-equity ratio of 6.65, a quick ratio of 1.46 and a current ratio of 2.31. The company has a market cap of $1.05 billion, a price-to-earnings ratio of 173.50, a PEG ratio of 0.18 and a beta of 1.17. The stock’s 50 day moving average price is $3.95. Amneal Pharmaceuticals has a 52 week low of $3.08 and a 52 week high of $6.21.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The company reported $0.10 EPS for the quarter, meeting the consensus estimate of $0.10. Amneal Pharmaceuticals had a net margin of 0.08% and a return on equity of 53.73%. The business had revenue of $497.63 million for the quarter, compared to the consensus estimate of $500.68 million. Analysts anticipate that Amneal Pharmaceuticals will post 0.74 EPS for the current year.

Amneal Pharmaceuticals Company Profile (Get Rating)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Featured Stories